MedTrace Logo

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

NCT01812954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2017-08-11

No results posted yet for this study

Summary

This study is health economic analysis of medicinal treatment options for moderate-to-severe psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various different sources, including summary of product characteristics (SPCs) and the German S3 guideline on psoriasis care, health care utilization data and official statistics.

The study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as well as indirect cost will be considered.

Conditions

Interventions

DRUG

Methotrexate

DRUG

Cyclosporins

DRUG

fumaric acid

DRUG

Acitretin

DRUG

Infliximab

DRUG

etanercept

DRUG

Adalimumab

DRUG

Ustekinumab

Sponsors & Collaborators

Principal Investigators

  • Jochen Schmitt, MD, MPH · University Dresden

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-06-30
Completion
2014-06-30

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01812954 on ClinicalTrials.gov